Further, as noted above, the thymidylate synthase inhibitor CT900 (ONX0801) is transported into EOCs by FRα [26] and has shown promising clinical activity toward FRα-overexpressing high-grade serous ovarian cancer [126]. The gene discussed is FOLR1; the disease is ovarian serous adenocarcinoma.